Belantamab mafodotin
As of the edition of 20 October 2026, Belantamab mafodotin is an antibody drug conjugate: marketed, first approved in 2020 (US); acts on TNFRSF17, TUBB and TUBB1 and 7 more; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody drug conjugate
- Brand name
- Blenrep
- First approved
- 5 August 2020 (US)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- GSK; 3 holders in all
- Withdrawn from market
- 23 February 2024 (in some regions)
- Registered trials
- 73, 11 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Eye; Nutrition and metabolism
US protection
US protection ends in 2032.
US protection ends in 2032, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by GSK. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Belantamab mafodotin.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 1 | 1 |
| Phase 1 | 13 | 3 | 7 | 3 |
| Phase 2 | 46 | 6 | 32 | 6 |
| Phase 3 | 9 | 0 | 8 | 1 |
| All trials | 73 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Originator, Applicant and Lead sponsor of trials | 2014 to now |